Table 3 Comparison of clinical variables between subjects with/without complete remission (CR) by mean difference and relative risk (RR)

Mean ± SD

Mean ± SD

Mean difference (95% CI)

P value

Latency to CBZ treatment (yrs)

11.86 ± 8.07

9.70 ± 6.96

2.16 (−0.47, 4.78)

0.106

Period after CBZ treatment (yrs)

9.49 ± 5.04

11.31 ± 5.23

−1.82 (−3.61, −0.03)

0.046

Episode before treatment

2.57 ± 2.13

3.32 ± 2.23

−0.75 (−1.51, 0.01)

0.054

Episode after treatment

0

2.65 ± 1.86

−2.65 (−3.11, −2.19)

<0.001

Drug dose (mg)

539.68 ± 187.98

601.52 ± 231.05

−61.83 (−135.42, 11.75)

0.099

Drug level (μg/mL)

7.22 ± 1.94

8.38 ± 8.03

−1.15 (−3.26, 0.95)

0.280

Age (yrs)

46.99 ± 11.17

44.55 ± 10.58

2.44 (−1.35, 6.23)

0.205

N (%)

N (%)

RR (95% CI)

P value

Gender (female)

35 (55.6)

49 (74.2)

0.75 (0.58, 0.97)

0.026

Tobacco use

9 (14.5)

15 (22.7)

1.11 (0.94, 1.31)

0.234

Alcohol use n

5 (8.1)

5 (7.6)

1.00 (0.90, 1.10)

0918

Combined use of antipsychotics

36 (57.1)

52 (78.8)

2.02 (1.17, 3.49)

0.008

Combined use of BZD n

45 (71.4)

51 (77.3)

1.26 (0.70, 2.27)

0.447

Combined use of lithium

24 (38.1)

26 (39.4)

1.02 (0.78, 1.34)

0.880

Combined use of valproic acid

10 (15.9)

6 (9.1)

0.93 (0.81, 1.06)

0.243

Combined use of antidepressant

6 (9.5)

8 (12.1)

1.03 (0.91, 1.16)

0.635